Lanean...
In vivo genome editing of ANGPTL3:a potential therapeutic strategy for coronary atherosclerosis?
Hyperlipidemia is an important risk factor for coronary heart disease. Chadwick and colleagues report significantly reduced blood lipid levels following CRISPR-based in vivo genome editing in mice to introduce loss-of-function mutations in ANGPTL3, a lipoprotein lipase inhibitor. The treatments were...
Gorde:
| Argitaratua izan da: | Nat Rev Cardiol |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6432938/ https://ncbi.nlm.nih.gov/pubmed/29618844 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrcardio.2018.38 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|